Ipsen Biopharmaceuticals, Inc.
1 Main Street
About Ipsen Biopharmaceuticals, Inc.
Ipsen (Euronext: IPN; ADR: IPSEY) is a global, biopharmaceutical group focused on innovation and specialty care. The group develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Neuroscience and Rare Diseases. At Ipsen, we focus our resources, investments and energy on discovering, developing and commercializing new therapeutic options to provide hope for patients whose lives are challenged by difficult-to-treat diseases. Ipsen's North American operations and headquarters are located in Cambridge, Massachusetts, where our fully integrated biopharmaceutical team across External Innovation and Partnering, Research & Development (R&D), Manufacturing and Commercial collaborate. Cambridge is home to Ipsen's third global hub, in addition to R&D centers in Paris-Saclay in France and Oxford in the United Kingdom. With additional offices in Basking Ridge, N.J. and Mississauga, Ontario, Ipsen employs approximately 600 people in North America. For more information on Ipsen in North America, please visit www.ipsenus.com or www.ipsen.ca.
570 articles about Ipsen Biopharmaceuticals, Inc.
Ipsen And GTx, Inc. Enter Into Partnership Agreement For The European Rights Of Acapodene(R); Deal Could Be Worth $80.8 Million
Ipsen's First Half 2006 Results
The Day In Review: Tercica, Inc. And Ipsen Sign Cross-License Deal
Ipsen Signs Roche Deal And Sets Foot In U.S.; Roche Will Pay Ipsen $74 Million
Ipsen And Tercica, Inc. To Enter Into Worldwide Strategic Collaboration In Endocrinology
Ipsen To Grant Medicis Pharmaceutical Rights To Distribute And Promote Ipsen's Botulinum Toxin Product To The Aesthetic Market
Radius Announces Licensing Agreement For Ipsen Osteoporosis Proprietary Molecule BA058
Ipsen Sets IPO Price Near Low-End Of Range
Ipsen Aims To Raise €400 Million In IPO
Ipsen Joins Pfizer In Breast Cancer Trials